James M Angelastro
Overview
Explore the profile of James M Angelastro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
893
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sun X, Angelastro J, Merino D, Zhou Q, Siegelin M, Greene L
Cell Death Dis
. 2019 Sep;
10(10):709.
PMID: 31551409
Survivin (BIRC5, product of the BIRC5 gene) is highly expressed in many tumor types and has been widely identified as a potential target for cancer therapy. However, effective anti-survivin drugs...
12.
Sears T, Angelastro J
Oncotarget
. 2017 Nov;
8(48):84595-84609.
PMID: 29137451
Activating transcription factor 5 (ATF5) is a cellular prosurvival transcription factor within the basic leucine zipper (bZip) family that is involved in cellular differentiation and promotes cellular adaptation to stress....
13.
Angelastro J
Trends Cancer
. 2017 Jul;
3(7):471-474.
PMID: 28718401
The expression of activating transcription factor 5 (ATF5) correlates negatively with patient survival in different types of cancer. ATF5 is important for the survival and proliferation of cancer cells, and...
14.
Karpel-Massler G, Horst B, Shu C, Chau L, Tsujiuchi T, Bruce J, et al.
Clin Cancer Res
. 2016 Apr;
22(18):4698-711.
PMID: 27126996
Purpose: Despite significant progress in cancer research, many tumor entities still have an unfavorable prognosis. Activating transcription factor 5 (ATF5) is upregulated in various malignancies and promotes apoptotic resistance. We...
15.
Cates C, Arias A, Nakayama Wong L, Lame M, Sidorov M, Cayanan G, et al.
Oncotarget
. 2016 Feb;
7(11):12718-30.
PMID: 26863637
Malignant gliomas have poor prognosis and urgently require new therapies. Activating Transcription Factor 5 (ATF5) is highly expressed in gliomas, and interference with its expression/function precipitates targeted glioma cell apoptosis...
16.
Lee H, Angelastro J, Kenney A, Mason C, Greene L
Dev Neurobiol
. 2011 Nov;
72(6):789-804.
PMID: 22095825
Precise regulation of neuroprogenitor cell proliferation and differentiation is required for successful brain development, but the factors that contribute to this are only incompletely understood. The transcription factor ATF5 promotes...
17.
Cunningham C, Martinez Cerdeno V, Navarro Porras E, Prakash A, Angelastro J, Willemsen R, et al.
Hum Mol Genet
. 2010 Oct;
20(1):64-79.
PMID: 20935171
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late adult-onset neurodegenerative disorder caused by a premutation CGG-trinucleotide repeat expansion (55-200 CGG repeats) within the 5'-untranslated region of the FMR1 gene. Although...
18.
Angelastro J, Lame M
Mol Cancer Res
. 2010 Jul;
8(8):1105-15.
PMID: 20663862
Glioblastoma multiforme is an extremely aggressive and clinically unresponsive form of cancer. Transformed neoplastic neural stem cells, resistant to chemotherapy and radiation therapy, are thought to be responsible for the...
19.
Li G, Li W, Angelastro J, Greene L, Liu D
Mol Cancer Res
. 2009 Jun;
7(6):933-43.
PMID: 19531563
Recent reports indicate that the activating transcription factor 5 (ATF5) is required for the survival of cancer cells but not for noncancer cells. However, the mechanisms by which ATF5 regulates...
20.
Greene L, Lee H, Angelastro J
J Neurochem
. 2008 Dec;
108(1):11-22.
PMID: 19046351
We review recent findings regarding the properties of ATF5 and the major roles that this transcription factor plays in development of the nervous system and in survival of neural tumors....